Detection of specific antigens in immune-mediated cerebellar ataxias
Objective: We aimed to clarify biomarkers and pathogenic autoantibodies in cerebellar ataxia, especially multiple system atrophy (MSA) and immune-mediated cerebellar ataxias (IMCAs), by detection of…COMBINED CSF α-SYN RT-QuIC, CSF NFL AND MIDBRAIN-PONS PLANIMETRY IN DEGENERATIVE PARKINSONISMS: FROM BEDSIDE TO BENCH, AND BACK AGAIN
Objective: (1) to assess the combined diagnostic ability of CSF NFL, CSF RT-QuIC α-SYN and midbrain/pons MRI measures in degenerative parkinsonisms; (2) to interpret results…The acceptability of wearable devices to measure mobility in people with Parkinson’s Disease: observations from Mobilise-D
Objective: To explore the acceptability of wearable devices to remotely measure mobility in the Mobilise-D technical validation study (TVS). Background: When deploying tools to monitor…Highlighting the dystonic phenotype related to GNAO1
Objective: To characterize the clinical and genetic features of patients with mild GNAO1-related phenotype with prominent movement disorders. Background: Most reported patients carrying GNAO1 mutations…Developing infrastructure for a multi-arm multi-stage trial in Parkinson’s
Objective: To scope and develop infrastructure for the first multi-arm multi-stage (MAMS) platform trial for Parkinson’s disease, the Edmond J Safra ACT-PD initiative (EJS ACT-PD).…Newly identified cases of parkinsonism and prodromal PD in a remote LRRK2 G2019S cohort
Objective: To evaluate new cases of prodromal PD and concern for parkinsonism in a cohort of LRRK2 G2019S carriers. Background: LRRK2 G2019S is a common…Clinical Characteristics of patients with Parkinson’s disease showing normal values on SBR in the DAT SPECT
Objective: The aim of this study was to clarify what the ‘normal’ values of the specific binding ratio (SBR), a measure of striatal radiotracer uptake…Telemedicine in a Himalayan country: unlocking the barrier in the management of Parkinson’s Disease
Objective: To evaluate the feasibility of telemedicine among PD patients in Nepal. Background: Nepal is a mountainous country occupying about 85% by Himalayas and hills…IPX203 dose conversion from immediate-release carbidopa-levodopa, in Parkinson’s disease patients with motor fluctuations.
Objective: To analyze dosing regimen data from a Phase 3 study in order to identify an optimal dose conversion from IR CD-LD to IPX203 for…Correlation between clinical scales and gait in Parkinson’s disease
Objective: The objective of this study is to verify the correlations between cognitive and motor clinical scales and gait in individuals with PD and whether…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 153
- Next Page »